Evolus Inc (EOLS)

$5.26 -0.09 (-1.68%)
Market Cap 359.78M
Revenue (ttm) 266.27M
Net Income (ttm) -50.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.94%
Debt to Equity Ratio -5.07
Volume 576,977
Avg Vol 1,380,240
Day's Range N/A - N/A
Shares Out 65.06M
Stochastic %K 58%
Beta 1.02
Analysts Strong Sell
Price Target $15.60

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 949 284 4555
Address:
520 Newport Center Drive, Suite 1200, Newport Beach, United States
FionaWagner_3
FionaWagner_3 Mar. 10 at 9:41 AM
$EOLS healthcare growth name, if it clears the range this could attract better momentum
0 · Reply
Mason_H88
Mason_H88 Mar. 6 at 8:48 PM
$EOLS thin biotech tape if buyers defend level watch accumulation shift
0 · Reply
SnackBandit34
SnackBandit34 Mar. 6 at 4:47 PM
$EOLS Back to 5 bucks.
0 · Reply
CEM97
CEM97 Mar. 5 at 4:16 PM
$EOLS this is $FIGS and $FSLY 2.0
0 · Reply
CEM97
CEM97 Mar. 5 at 3:48 PM
$EOLS if this revisits the highs today I could see $7 Friday or next week
0 · Reply
M105
M105 Mar. 5 at 2:53 PM
$EOLS and…
1 · Reply
M105
M105 Mar. 5 at 2:52 PM
$EOLS
0 · Reply
RocketThief
RocketThief Mar. 4 at 9:24 PM
$EOLS nice turnaround
0 · Reply
RunnerSignals
RunnerSignals Mar. 4 at 9:22 PM
top gainers in the buzz hit major highs today $ASNS $JZXN $BW $EOLS $CANF surge on contracts, crypto deals, earnings beats and clinical wins https://stocksrunner.com/news/2026-03-04-top-gainers-in-the-buzz-today
0 · Reply
Stackdoe101
Stackdoe101 Mar. 4 at 8:50 PM
$EOLS 🙃✨
0 · Reply
Latest News on EOLS
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript

Mar 4, 2026, 2:42 AM EST - 6 days ago

Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Mar 3, 2026, 4:05 PM EST - 6 days ago

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Feb 25, 2026, 8:00 AM EST - 13 days ago

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

Feb 17, 2026, 8:00 AM EST - 21 days ago

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 13, 2026, 4:05 PM EST - 24 days ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

Jan 9, 2026, 8:30 AM EST - 2 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

Dec 14, 2025, 11:30 PM EST - 3 months ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ABBV ALGT CGNX COHR INSP LTH MAT

Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript

Nov 8, 2025, 4:16 PM EST - 4 months ago

Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript

Evolus Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 4 months ago

Evolus Reports Third Quarter 2025 Financial Results

Evolus to Participate in 2025 Stifel Healthcare Conference

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Evolus to Participate in 2025 Stifel Healthcare Conference

Evolus to Report Third Quarter Financial Results on November 5, 2025

Oct 22, 2025, 8:00 AM EDT - 4 months ago

Evolus to Report Third Quarter Financial Results on November 5, 2025

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

Sep 22, 2025, 9:03 AM EDT - 6 months ago

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 12, 2025, 5:30 PM EDT - 6 months ago

Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Sep 8, 2025, 8:30 AM EDT - 6 months ago

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Aug 25, 2025, 8:00 AM EDT - 7 months ago

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Aug 20, 2025, 8:00 AM EDT - 7 months ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:15 PM EDT - 7 months ago

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 5, 2025, 4:05 PM EDT - 7 months ago

Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Jul 31, 2025, 8:05 AM EDT - 7 months ago

Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

Evolus to Report Second Quarter Financial Results on August 5, 2025

Jul 22, 2025, 8:05 AM EDT - 8 months ago

Evolus to Report Second Quarter Financial Results on August 5, 2025

Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings

Jul 21, 2025, 5:20 PM EDT - 8 months ago

Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Jul 9, 2025, 8:00 AM EDT - 8 months ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France

Evolysse™ Recognized in 2025 Shape Skin Awards

Jun 10, 2025, 8:00 AM EDT - 9 months ago

Evolysse™ Recognized in 2025 Shape Skin Awards

Evolus Announces Departure of its Chief Financial Officer

May 27, 2025, 4:15 PM EDT - 10 months ago

Evolus Announces Departure of its Chief Financial Officer

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 22, 2025, 8:00 AM EDT - 10 months ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:13 PM EDT - 10 months ago

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

Evolus Reports First Quarter 2025 Results

May 7, 2025, 4:05 PM EDT - 10 months ago

Evolus Reports First Quarter 2025 Results

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

May 5, 2025, 4:05 PM EDT - 11 months ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 11 months ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Evolus Announces Commercial Launch of Evolysse™

Apr 16, 2025, 8:00 AM EDT - 11 months ago

Evolus Announces Commercial Launch of Evolysse™

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Apr 15, 2025, 8:00 AM EDT - 11 months ago

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:18 PM EST - 1 year ago

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Evolus posts quarterly profit on strong sales of cosmetic injection

Mar 4, 2025, 4:17 PM EST - 1 year ago

Evolus posts quarterly profit on strong sales of cosmetic injection

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Mar 4, 2025, 4:05 PM EST - 1 year ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Feb 27, 2025, 8:00 AM EST - 1 year ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Feb 20, 2025, 8:00 AM EST - 1 year ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Feb 18, 2025, 8:00 AM EST - 1 year ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:45 PM EST - 1 year ago

US FDA approves Evolus' anti-wrinkle gels

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Feb 13, 2025, 1:30 PM EST - 1 year ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Jan 21, 2025, 8:00 AM EST - 1 year ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Jan 14, 2025, 2:00 PM EST - 1 year ago

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 7:28 PM EST - 1 year ago

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Evolus Reports Third Quarter 2024 Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 31, 2024, 2:02 PM EDT - 1 year ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 10:22 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

FionaWagner_3
FionaWagner_3 Mar. 10 at 9:41 AM
$EOLS healthcare growth name, if it clears the range this could attract better momentum
0 · Reply
Mason_H88
Mason_H88 Mar. 6 at 8:48 PM
$EOLS thin biotech tape if buyers defend level watch accumulation shift
0 · Reply
SnackBandit34
SnackBandit34 Mar. 6 at 4:47 PM
$EOLS Back to 5 bucks.
0 · Reply
CEM97
CEM97 Mar. 5 at 4:16 PM
$EOLS this is $FIGS and $FSLY 2.0
0 · Reply
CEM97
CEM97 Mar. 5 at 3:48 PM
$EOLS if this revisits the highs today I could see $7 Friday or next week
0 · Reply
M105
M105 Mar. 5 at 2:53 PM
$EOLS and…
1 · Reply
M105
M105 Mar. 5 at 2:52 PM
$EOLS
0 · Reply
RocketThief
RocketThief Mar. 4 at 9:24 PM
$EOLS nice turnaround
0 · Reply
RunnerSignals
RunnerSignals Mar. 4 at 9:22 PM
top gainers in the buzz hit major highs today $ASNS $JZXN $BW $EOLS $CANF surge on contracts, crypto deals, earnings beats and clinical wins https://stocksrunner.com/news/2026-03-04-top-gainers-in-the-buzz-today
0 · Reply
Stackdoe101
Stackdoe101 Mar. 4 at 8:50 PM
$EOLS 🙃✨
0 · Reply
StockJelli
StockJelli Mar. 4 at 8:39 PM
Last 20 min of power hour. Here are the momentum tickers. $BDMD $EOLS $GEMI $DAWN $ZIP
0 · Reply
SnackBandit34
SnackBandit34 Mar. 4 at 8:36 PM
$EOLS Let’s go back to 5🔥🔥
0 · Reply
raiderguy12
raiderguy12 Mar. 4 at 8:01 PM
$EOLS Let's hit 7
0 · Reply
CEM97
CEM97 Mar. 4 at 6:46 PM
$EOLS a lot to like here. Reminds me of $FIGS
0 · Reply
StockJelli
StockJelli Mar. 4 at 6:34 PM
Ok here is another check of momentum stocks happening now 👇 $SHMD $EOLS $ZIP $GOSS $SWIM
0 · Reply
Scamstock
Scamstock Mar. 4 at 6:29 PM
$EOLS
0 · Reply
Hottehueh
Hottehueh Mar. 4 at 5:39 PM
$EOLS great q4 and good outlook.
0 · Reply
CEM97
CEM97 Mar. 4 at 5:17 PM
$EOLS 👀
0 · Reply
topstockalerts
topstockalerts Mar. 4 at 5:06 PM
$EOLS extended after catalyst release, now pivoting to base; watch next accumulation and volume — reset or continuation?
1 · Reply
Nakuldesai
Nakuldesai Mar. 4 at 4:31 PM
$EOLS dump and dump. Garbage
0 · Reply
CEM97
CEM97 Mar. 4 at 3:39 PM
$EOLS $6 seems obvious
0 · Reply
Capitulation_0
Capitulation_0 Mar. 4 at 3:14 PM
$EOLS Bios in general are mispriced. Sell off has been brutal for this name and many others. Price discovery and valuations are broken. Hopefully bios get better price action soon.
0 · Reply